GEC-ESTRO随机III期试验:早期乳腺癌保乳术后组织间插植加速部分乳腺照射与全乳照射的5年生活质量结果
GEC-ESTRO随机III期试验在633例接受加速部分乳腺照射(APBI)和551例接受全乳照射的早期乳腺癌患者中比较5年生活质量。两组整体健康状况稳定且无显著差异,仅全乳照射组乳房症状评分在放疗后即刻和3个月随访时显著更差。结论认为APBI不降低生活质量,可作为保乳术后替代治疗选择。
要点
- 全乳照射组乳房症状评分在放疗后即刻和3个月随访时显著高于APBI组。
- APBI可作为早期乳腺癌保乳术后替代治疗选择,不降低生活质量。
核心结论
- 组织间插植APBI与全乳照射相比未导致更差的生活质量,支持APBI作为早期乳腺癌保乳术后替代治疗选择。
研究设计与样本
- 随机对照III期试验,在7个欧洲国家16家医院和医疗中心开展,2004年4月20日至2009年7月30日入组。
- 患者年龄≥40岁、0-IIA期乳腺癌、保乳术后切缘≥2 mm,1:1随机分配至全乳照射50 Gy加10 Gy推量或组织间插植APBI。
- 按实际接受治疗分析,APBI组633例、全乳照射组551例;基线1生活质量问卷APBI组334/663例(53%)、全乳照射组314/551例(57%)可获取。
临床怎么用
- 对于早期乳腺癌保乳术后患者,APBI可作为全乳照射的替代选择,不增加生活质量负担。
局限性
- 患者和研究者未设盲。
- 生活质量问卷基线1应答率APBI组53%、全乳照射组57%,随访期应答率相似。
- 分析基于实际接受治疗人群,非意向治疗人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous results from the GEC-ESTRO trial showed that accelerated partial breast irradiation (APBI) using multicatheter brachytherapy in the treatment of early breast cancer after breast-conserving surgery was non-inferior to whole-breast irradiation in terms of local control and overall survival. Here, we present 5-year results of patient-reported quality of life. METHODS: We did this randomised controlled phase 3 trial at 16 hospitals and medical centres in seven European countries. Patients aged 40 years or older with 0-IIA breast cancer were randomly assigned (1:1) after breast-conserving surgery (resection margins ≥2 mm) to receive either whole-breast irradiation of 50 Gy with a boost of 10 Gy or APBI using multicatheter brachytherapy. Randomisation was stratified by study centre, tumour type, and menopausal status, with a block size of ten and an automated dynamic algorithm. There was no masking of patients or investigators. The primary endpoint of the trial was ipsilateral local recurrence. Here, we present 5-year results of quality of life (a prespecified secondary endpoint). Quality-of-life questionnaires (European Organisation for Research and Treatment of Cancer QLQ-C30, breast cancer module QLQ-BR23) were completed before radiotherapy (baseline 1), immediately after radiotherapy (baseline 2), and during follow-up. We analysed the data according to treatment received (as-treated population). Recruitment was completed in 2009, and long-term follow-up is continuing. The trial is registered at ClinicalTrials.gov, number NCT00402519. FINDINGS: Between April 20, 2004, and July 30, 2009, 633 patients had accelerated partial breast irradiation and 551 patients had whole-breast irradiation. Quality-of-life questionnaires at baseline 1 were available for 334 (53%) of 663 patients in the APBI group and 314 (57%) of 551 patients in the whole-breast irradiation group; the response rate was similar during follow-up. Global health status (range 0-100) was stable in both groups: at baseline 1, APBI group mean score 65·5 (SD 20·6) versus whole-breast irradiation group 64·6 (19·6), p=0·37; at 5 years, APBI group 66·2 (22·2) versus whole-breast irradiation group 66·0 (21·8), p=0·94. The only moderate, significant difference (difference of 10-20 points) between the groups was found in the breast symptoms scale. Breast symptom scores were significantly higher (ie, worse) after whole-breast irradiation than after APBI at baseline 2 (difference of means 13·6, 95% CI 9·7-17·5; p<0·0001) and at 3-month follow-up (difference of means 12·7, 95% CI 9·8-15·6; p<0·0001). INTERPRETATION: APBI with multicatheter brachytherapy was not associated with worse quality of life compared with whole-breast irradiation. This finding supports APBI as an alternative treatment option after breast-conserving surgery for patients with early breast cancer. FUNDING: German Cancer Aid.
引用
- Schäfer R, Strnad V, Polgár C, et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncol. 2018. PMID: 29695348. doi:10.1016/S1470-2045(18)30195-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。